trial

Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia

NCTId NCT04414930
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 68 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2024-12-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
68 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2020-11-09
Primary completion
2024-12-30
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
d-amphetamine

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Investigators

1
Neal R. Swerdlow, M.D., Ph.D.Principal Investigator

Sites

1 total
San Diego, United States

Linked catalysts

1
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia — primary completion2024-12-30

Facts & assertions

4 sourced
Enrollment
68
Phase
PHASE2
Primary Completion Date
2024-12-30
Status
COMPLETED
relationships
The graph out of here
drug
d-amphetamine
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Neal R. Swerdlow, M.D., Ph.D.
person